Skip to main content

#151316

Anti-FIH [FIH162C]

Cat. #151316

Anti-FIH [FIH162C]

Cat. #: 151316

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: Factor Inhibiting HIF1 (FIH)

Class: Monoclonal

Application: IHC ; IF ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Helen Turley

Institute: University of Oxford

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-FIH [FIH162C]
  • Research fields: Cancer;Genetics
  • Clone: FIH162C
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 40 kDa
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC ; IF ; WB
  • Description: FIH, Factor Inhibiting HIF1 (Hypoxia-Inducible Factor), is an asparaginyl hydroxylase. FIH in conjunction with VHL represses HIF-1 transcriptional activity by disrupting the interaction of HIF-1 with the transcriptional coactivators CBP/p300, and by recruiting histone deacetylases. FIH activity is inhibited during hypoxia.
  • Immunogen: Full length human FIH expressed in Escherichia coli BL21(DE3) cells.
  • Isotype: IgG1
  • Myeloma used: P3/NS1/1-Ag4.1
  • Recommended controls: MCF7 cells

Target Details

  • Target: Factor Inhibiting HIF1 (FIH)
  • Molecular weight: 40 kDa
  • Tissue cell line specificity: MCF7 cells
  • Target background: FIH, Factor Inhibiting HIF1 (Hypoxia-Inducible Factor), is an asparaginyl hydroxylase. FIH in conjunction with VHL represses HIF-1 transcriptional activity by disrupting the interaction of HIF-1 with the transcriptional coactivators CBP/p300, and by recruiting histone deacetylases. FIH activity is inhibited during hypoxia.

Applications

  • Application: IHC ; IF ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Dry ice

References

  • Wollenick et al. 2012. Nucleic Acids Res. 40(5):1928-43. PMID: 22075993.
  • Synthetic transactivation screening reveals ETV4 as broad coactivator of hypoxia-inducible factor signaling.
  • Yan et al. 2009. Br J Cancer. 101(7):1168-74. PMID: 19724277.
  • BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression.
  • Cockman et al. 2006. Proc Natl Acad Sci U S A. 103(40):14767-72. PMID: 17003112.
  • Posttranslational hydroxylation of ankyrin repeats in IkappaB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH).
  • Soilleux et al. 2005. Histopathology. 47(6):602-10. PMID: 16324198.
  • Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues.
  • Stolze et al. 2004. J Biol Chem. 279(41):42719-25. PMID: 15302861.
  • Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (FIH) in regulating hypoxia-inducible factor (HIF) transcriptional target genes [corrected].

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.